The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine - preliminary 24 week results: Robert Perillo, Alton L Oschner Clin, New Orleans, LA; Eugene Schiff, Univ of Miami, Miami, FL; Hie-Won L Hann, Jefferson Medical Coll, Philadelphia, PA; Maria Buti, Hosp Valle de Hebron, Barcelona Spain; Simone Strasser, Royal Prince Alfred Hosp, Camperdown, New South Wales Australia; Karen M Watkins, Alison E Moorat, GlaxoSmithKline R&D, Greenford, Middlesex, Uk; Mary A Woesnner, GlasoSmithKline R&D, Research Triangle Park, NC; Pamela Vig, Carol L Brosgart, Gilead Sciences, Foster City, CA; Eric C Bourne, GlaxoSmithKline Virology Lab, Research Triangle Park; Mark C Atkins, GlaxoSmithKline R&D, Greenford, Middlesex Uk